Search - tctmd.com

Displaying 1 - 20 of 49

Sort: Relevancy | Date

RE-DUAL PCI Findings Consistent Across Key Subgroups

News Conference News AHA 2017

RE-DUAL PCI Findings Consistent Across Key Subgroups

November 16, 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

Angiography, Revascularization Safe in Acute MI Patients Taking OACs for Atrial Fibrillation

News Conference News AHA 2017

Angiography, Revascularization Safe in Acute MI Patients Taking OACs for Atrial Fibrillation

Michael O'Riordan

November 13, 2017

Better PCI Outcomes Not Guaranteed at Top-Ranked Hospitals

News Conference News AHA 2017

Better PCI Outcomes Not Guaranteed at Top-Ranked Hospitals

November 12, 2017

FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost

News Conference News TCT 2017

FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost

November 02, 2017

ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure

News Conference News TCT 2017

ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure

Michael O'Riordan

November 02, 2017

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

News Conference News TCT 2017

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

November 01, 2017

REVASCTO PCI Does Not Improve LV Function but Seems to Provide Symptom Relief

News Conference News TCT 2017

REVASC: CTO PCI Does Not Improve LV Function but Seems to Provide Symptom Relief

October 31, 2017

Long-term Absorb BVS Data Continue to Disappoint

News Conference News TCT 2017

Long-term Absorb BVS Data Continue to Disappoint

Michael O'Riordan

October 31, 2017

Live From Denver: TCT 2017, Day Two

News Conference News TCT 2017

Live From Denver: TCT 2017, Day Two

October 31, 2017

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

News Conference News TCT 2017

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

Michael O'Riordan

October 30, 2017

Live From Denver: TCT 2017, Day One

News Conference News TCT 2017

Live From Denver: TCT 2017, Day One

October 30, 2017

No Late Quality of Life Trade-offs With PCI in Left Main Disease: EXCEL-QOL Substudy

News Conference News TCT 2017

No Late Quality of Life Trade-offs With PCI in Left Main Disease: EXCEL-QOL Substudy

Michael O'Riordan

October 30, 2017

CULPRIT-SHOCK Disputes Benefit of Immediate Multivessel PCI in Patients With Cardiogenic Shock

News Conference News TCT 2017

CULPRIT-SHOCK Disputes Benefit of Immediate Multivessel PCI in Patients With Cardiogenic Shock

October 30, 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

October 20, 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

September 18, 2017

EVAR Outcomes Equivalent Between Men and Women, Registries Show

News Conference News VIVA 2017

EVAR Outcomes Equivalent Between Men and Women, Registries Show

September 14, 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.